Artiva Biotherapeutics, Inc. ARTV Cash Cash Equivalents And Short Term Investments
Cash Cash Equivalents And Short Term Investments at other companies
Other financials
Where this comes from
Reported directly by Artiva Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsAndShortTermInvestments.
The official record: Artiva Biotherapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Artiva Biotherapeutics, Inc.'s cash cash equivalents and short term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Artiva Biotherapeutics, Inc.'s cash cash equivalents and short term investments?
- Artiva Biotherapeutics, Inc. (ARTV) reported cash cash equivalents and short term investments of $86.8M in Q1 2026.
- How has Artiva Biotherapeutics, Inc.'s cash cash equivalents and short term investments changed year-over-year?
- Artiva Biotherapeutics, Inc.'s cash cash equivalents and short term investments decreased by 47.7% year-over-year, from $166M to $86.8M.